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Background. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) infection elicits inflammatory manifestations that
relate with a “cytokine storm.” Objective. The aim of this research was to assess the role of circulating interleukin 6 (IL-6) levels and
other inflammatory markers in patients with coronavirus disease 2019 (COVID-19) on metabolic functions and accompanying
clinical complications. Patients and Methods. A total of 165 patients diagnosed with COVID-19 pneumonia were examined for
medical features and inflammatory markers such as blood IL-6, CRP, ferritin, LDH, neutrophil/lymphocyte index (NLI), D-
Dimer, and Red Cell Distribution Width (RDW). Regression analyses concerning electronically collected medical data were
adjusted by appropriate factors and confounding variables. Results. Plasma IL-6 determinations evidenced a consistent
association with hospital stay days, Intensive Care Unit (ICU) admission, and mortality rates. Similar trends were found for
other proinflammatory variables, where ferritin and NLI showed a remarkable value as surrogates. Hyperglycaemia and the
Charlson Comorbidity Index Score were positively associated with the inflammatory response induced by the SARS-COV-2
infection. An unhealthy lifestyle such as smoking and alcoholic drinks consumption as well as excessive body adiposity
influenced inflammatory-related outcomes in the screened patients. Conclusion. IL-6 together with other inflammatory
biomarkers accompanied poor clinical and metabolic outcomes in COVID-19-infected patients. IL-6 may result in a suitable
proxy to individually categorise patients in order to manage this infectious pandemic.
1. Introduction
Coronavirus disease 2019 (COVID-19) has rapidly spread
around the world being declared as a pandemic by the World
Health Organization (WHO) in March 2020 [1]. This situa-
tion is based on a high transmission rate, lethality, medical
progression uncertainties, and the lack of satisfactory antivi-
ral treatments [2, 3]. Thousands of COVID-19 cases have
been reported encompassing a wide spectrum of symptoms
[4]. The respiratory system was the most frequently affected
by the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-COV-2), with patients presenting mild illness as well
as more severe features such as acute respiratory distress syn-
drome (ARDS) requiring admission in Intensive Care Units
(ICU) and specific medical attention [5]. Gastrointestinal
problems such as diarrhoea or vomiting and haematological
and dermatological findings have also been described in
COVID-19-infected patients [6].
The average incubation period for COVID-19 is 6 to 7
days, lasting the first viremic phase from 8 to 10 days, which
in most cases was followed by infection resolution [7].
However, the remaining patients progress to a second
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phase—called the inflammatory stage—featuring ARDS,
thromboembolic events, and myocardial acute injury, which
regrettably involves poor prognosis linked to an exacerbation
of the immune system cascade [8].
Clinical manifestations in COVID-19 patients correlate
with a phenomenon known as “cytokine storm” [9]. Thus,
the major burden occurs when the host immune response
to the virus is inadequate [10]. The process initiates with
SARS-CoV-2 entering into cells, which is followed by an
interaction with surface receptors (angiotensin-converting
enzyme 2 receptor—ACE2-). Most of these receptors are
located in epithelial type 2 cells from the upper respiratory
tract, which leads to damage-associated molecules delivering
with a subsequent activation of the innate immune system.
Epithelial and endothelial cells as well as macrophages are
then triggered, which release IL-6, IP-10 (interferon
gamma-induced protein-10), MIG chemokine, and MCP-1
(monocyte chemoattractant protein-1) mediators and gener-
ate further inflammation with the involvement of monocytes
and T cells.
Interleukin-6 (IL-6) has been identified as an essential
proinflammatory molecule mediating the activation of the
Janus kinase-signal transducer and transcription (JAK-
STAT) pathway, which produces oxidative stress, cell prolif-
eration, and a virus clearing default within a process called
“second wave in cytokine storm” [11]. Downregulating the
Suppressor of Cytokine Signalling 3 (SOCS3) may partially
explain the elevated serum IL-6 levels in those patients with
the most worrying symptomatology [12]. Understanding
these mechanisms is especially valuable considering the
proposed administration of anti-inflammatory drugs to
COVID-19-infected patients [13, 14].
Mortality rates associated to COVID-19 are diverse
among studies, ranging from 3% to 15% [15]. These varia-
tions are probably attributable to the different sample size,
origin, diagnostic criteria, and applied tests among investiga-
tions. Several epidemiological analyses have evidenced that
almost 15% of patients required ICU admission receiving
mechanical ventilation and implying longer hospitalisation
stays [16], which was also dependent of the baseline meta-
bolic and clinical status [1].
The aim of this study was to evaluate the influence of the
proinflammatory profile as categorised by the IL-6 levels in
patients infected by SARS-COV-2, including the assessment
of potential associations with other inflammatory biomarkers
and the personalised impact of the inflammatory status on
clinical outcomes.
2. Material and Methods
This investigation is a retrospective, cross-sectional, and
single-centre study encompassing a cohort of 165 consecu-
tively admitted patients to the Puerta de Hierro Hospital
in Majadahonda (Madrid, Spain) between March and
April 2020.
Adult subjects diagnosed with COVID-19 pneumonia
according to the WHO directions were recruited. The
WHO criteria were followed including cases presenting
clinical signs of pneumonia (fever, cough, dyspnoea, fast
breathing) plus respiratory rate > 30 breaths/min, severe
respiratory distress, or SpO2 < 90% on room air [17]. Every
patient had a positive PCR for SARS-COV-2 and an IL-6
measurement at admission, which was assessed following
the habitual hospital laboratory operative procedures. After
data collection and analysis, the participants were stratified
into three groups of patients based on the interleukin mea-
surement: patients with IL-6 between 0 and 10 pg/ml,
patients with IL-6 between 10 and 100pg/ml, and patients
with IL-6 greater than 100 pg/ml [7].
At admission, study variables related to proinflammatory
factors and prognosis were age, sex, IL-6 value, leukocyte
counts, neutrophil/lymphocyte index (NLI), and transami-
nases as well as Gamma Glutamyl Transpeptidase (GGT),
C-reactive Protein (CRP), lactate dehydrogenase (LDH), fer-
ritin, total cholesterol, baseline blood glucose, D-Dimer, and
Red Cell Distribution Width (RDW), which were analysed
following the hospital standardised protocols. The extraction
date was registered considering the first day of admission as
the baseline. The outcome variables were hospital stay days,
admission to the ICU, and mortality. Our alternative phras-
ing: Information about smoking and drinking as well as body
weight and height to estimate the body mass index (kg/m2)
were also compiled in the clinical history besides data
required in the Charlson Comorbidity Index Score.
Proinflammatory markers were collected from the emer-
gency checklist and from the admission analysis records. IL-6
quantification required ELISA (Sigma-Aldrich Human IL-6
ELISA Kit) and CBA (Cytometric Bead Array, BD Biosci-
ences) techniques with a later flow cytometry analysis as
described by the supplier. No extra blood samples were
required far from those needed for the clinical practice, since
all required markers were included as mandatory measure-
ments in the local COVID-19 disease protocol.
Data collection was performed through established elec-
tronic medical records (SELENE System, Cerner Iberia,
S.L.U, Madrid, Spain) with a standardised data collection
form. Two senior physicians reviewed all of them for consis-
tency. Data were anonymously used according to the autho-
rization of the Research Ethics Committee of our hospital
(PI94/20). This study complied with the guidelines involving
the EU and Spanish legislation on data protection and the
Declaration of Helsinki. The authors did not receive any
external source of funding, but were covered by their
employers.
Quantitative variables were expressed as means and
standard deviations while qualitative variables as frequencies
and percentages. For analysing the associations between
proinflammatory variables with the different IL-6 groups,
the chi-square test and analysis of variance (ANOVA) were
implemented. The statistical methods for multivariate analy-
sis were linear regression and logistic regression in order to
compute the crude odds ratios and their confidence interval.
Variables with a p value <0.05 in univariate models were
selected in the multivariable tests. To reduce the extraction
day bias and potential confounding variables, multivariable
models were adjusted by age, sex, Charlson Comorbidity
Index Score, main analytical values, and extraction day.
Moreover, appropriate covariables were fitted to adjust the
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regression models. The program used for the statistical pro-
cedures was the STATA platform (version 12.1 for Windows,
Texas, USA), whose manual and instructions were followed
to perform the analyses. The statistical significance level
was set at a two-sided p value of <0.05.
3. Results
The main clinical features of the cohort are summarised
(Table 1). Out of 165 participants, 66% were men and 33%
women. According to the IL-6 levels, there were 55 partici-
pants in each group. Forty-four percent presented arterial
hypertension, 53% dyslipidaemia, and 33% diabetes. The
average hospital stay days was 14 days, while 10% of the
participants died in hospital wards and 13.3% required
admission to the ICU.
The associations between serum IL-6 levels at admission
and other proinflammatory variables are reported (Table 2).
The relationships between IL-6 values and hospital stay days
resulted statistically significant (p < 0:001), as well as ICU
admission and mortality rate (p < 0:001). In addition, statis-
tically significant differences in Charlson Comorbidity Index
Score, ALT levels, CRP values, NLI, RDW, ferritin, and base-
line blood glucose were found.
Coefficients for hospital stay days adjusted by mediators
of inflammation in a multivariate model were calculated
(Table 3). The association with age and IL-6 levels was statis-
tically significant (p = 0:02 and p < 0:001, respectively). Coef-
ficients were standardised so that the variances of dependent
and independent variables are 1.
Associations between admission to ICU and the main
proinflammatory variables based on logistic regression
analyses are reported (Table 4). A statistically significant rela-
tionship was found between IL-6 levels and ICU admission
(p = 0:006).
The odds ratio for mortality and the associated relevance
of inflammatory biomarkers in a multivariate model are
displayed (Table 5). Age, sex, NLI, ferritin, and serum levels
of IL-6 showed a statistically significant association with in-
hospital mortality (p < 0:05).
4. Discussion
In our analyses, data from 165 successively admitted
patients with COVID-19 respiratory infection were studied,
being selected in three groups according to clinically
accepted IL-6 ranges. A multivariate model is presented
with other possible laboratory indicators including relevant
covariates. The analyses were performed following validated
laboratory techniques at the Central Biochemistry Unit of
the hospital, while suitable statistical methods were imple-
mented as advised.
Serum cytokine levels have been previously described as
important prognosis factors in other pandemic infectious
outbreaks [18]. Given the interindividual differences among
patients, precision pharmacological research and persona-
lised medicine are becoming clinically relevant [9, 19], which
demands the patient’s categorisation for individualized anti-
inflammatory management. Indeed, knowledge about
inflammatory patterns for subsequent subject stratification
may let the clinician to an earlier approach concerning the
patient situation to prevent adverse outcomes and prescribe
therapies according to specific pathological profiles [20].
Remarkable advantages of initial IL-6 assessment include to
be a minimally invasive determination, be easily accessible,
and be relatively inexpensive. Information provided by bio-
marker tools could contribute to understand the inflamma-
tory condition and individually treat this novel disease with
such an exponential growth [21].
Table 1: Clinical features concerning the enrolled COVID-19
population.
Variables Total (n = 165)





0-10 pg/ml 55 (33.3)
10-100 pg/ml 55 (33.3)
>100 pg/ml 55 (33.3)
Days of symptomatology at admission 7.6 (4.0)
Hypertension 66 (44.0)
Dyslipidaemia 53 (32.1)
Diabetes mellitus 33 (20.0)
Charlson Comorbidity Index Score 0.84 (1.42)
ALT (U/l) 40.6 (29.9)
AST (U/l) 51.1 (30.4)
GGT (U/l) 86.7 (95.1)
LDH (U/l) 358.1 (139.4)
CRP (mg/l) 132.8 (143.7)
Leukocytes (counts/μl) 7636 (3564)
NLI 7.9 (7.9)
RDW (%) 13.3 (1.2)
D-Dimer (μg/ml) 1.71 (5.44)
Ferritin (ng/ml) 1065.3 (917.6)
Total cholesterol (mg/dl) 138.8 (34.3)
SBP (mmHg) 137.8 (21.9)
DBP (mmHg) 79.1 (14.1)
Baseline blood glucose (mg/dl) 130.2 (59.1)
BMI (kg/m2) 28.4 (4.6)
Current smoker 11 (7.01)
Standard drink units 3.69 (23.07)
Hospital stay days 14.0 (13.1)
ICU admission 22 (13.3)
Mortality 16 (10.1)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT:
Gamma Glutamyl Transpeptidase; LDH: lactate dehydrogenase; CRP: C-
reactive Protein; NLI: Neutrophil/Lymphocyte index; RDW: Red Cell
Distribution Width; SBP: Systolic Blood Pressure; DBP: Diastolic Blood
Pressure; BMI: Body Mass Index; SD: standard deviation. ∗Qualitative
variables are expressed in number and proportion. Quantitative variables
are expressed in mean and standard deviation.
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A remarkable point of this study is the association
between objectively measured IL-6 serum levels and poor
prognosis determinants such as longer hospitalisation stays
besides higher ICU admission and mortality rates. Multiple
authors have reported that almost 80% of fatal cases
exhibited above-normal circulating IL-6 values [22]. The
Table 2: Association between IL-6 levels, clinical, anthropometrical, and biochemical determinants.
Group 1 IL − 6 > 100 pg/ml,
N = 55
Group 2 IL-6 10-100 pg/ml,
N = 55
Group 3 IL − 6 < 10 pg/ml,
N = 55 Chi
2/ANOVA p
Hypertension 26 (42.3) 25 (45.4) 15 (27.3) 5.61 0.06
Dyslipidemia 23 (41.8) 15 (27.3) 15 (27.3) 3.55 0.17
Diabetes mellitus 15 (27.3) 11 (20.0) 7 (12.7) 3.64 0.16
Charlson Comorbidity
Index Score
1.33 (1.66) 0.55 (1.02) 0.64(1.38) 12.68 0.006
ALT (U/l) 47.1 (20.1) 40.8 (22.9) 49.2 (43.0) 57.39 0.01
AST (U/l) 32.0 (15.0) 53.9 (22.8) 52.3 (43.2) 37.93 0.48
GGT (U/l) 71.4 (76.7) 109.9 (121.1) 79.2 (79.7) 15.42 0.08
LDH (U/l) 350.1 (117.6) 388.5 (149.0) 335.3 (157.0) 4.17 0.14
CRP (mg/dl) 182.1 (217.8) 127.9 (70.7) 88.2 (72.2) 90.67 0.02
Leucocytes (counts/μl) 7763 (4026) 7849.4 (3075) 7304 (3553) 3.76 0.69
NLI 10.9 (10.6) 7.2 (5.4) 5.6 (5.3) 34.56 0.001
RDW (%) 13.6 (1.3) 13.2 (1.2) 13.0 (0.9) 5.96 0.02
D-Dimer (μg/ml) 1.60 (2.11) 2.40 (9.01) 1.05 (0.96) 205.80 0.44
Ferritin (ng/ml) 1283(953) 1096 (874) 806 (877) 0.41 0.05
Total cholesterol (mg/dl) 135.3 (33.2) 139.5 (25.2) 145.6 (36.6) 7.60 0.20
SBP (mmHg) 139.2 (24.2) 138.1(21.3) 136.2 (20.3) 1.82 0.78
DBP (mmHg) 78.6 (14.4) 79.4 (12.8) 79.2 (15.3) 1.73 0.94
Baseline blood glucose
(mg/dl)
148.1 (77.0) 118.9(44.3) 120.9 (41.2) 24.49 0.01
BMI (kg/m2) 28.8 (4.5) 29.0 (5.0) 27.2 (3.9) 2.60 0.09
Current smoker 7 (12.7) 3 (5.4) 1 (1.8) 5.91 0.05
Drink standard units 8.76 (39.94) 1.74 (4.40) 0.78 (2.47) 1.87 0.15
NLI 2019 2.0 (3.5) 2.8 (4.2) 1.7 (0.8) 59.75 0.28
Hospital stay days 22.0 (17.1) 11.9 (10.4) 8.6 (5.8) 18.04 <0.001
ICU admission 16 (29.1) 4 (7.2) 2 (3.6) 18.04 <0.001
Mortality 13 (23.6) 3 (5.4) 0 (0.0) 20.67 <0.001
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: Gamma Glutamyl Transpeptidase; LDH: lactate dehydrogenase; CRP: C-reactive
Protein; NLI: Neutrophil/Lymphocyte index; RDW: Red Cell Distribution Width; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; BMI: Body
Mass Index. ∗Qualitative variables are expressed in number and proportion. Quantitative variables are expressed in mean and standard deviation.
Table 3: Coefficients for hospital stay days adjusted by age, sex, Charlson Comorbidity Index Score, and main analytical values in a linear
regression multivariate model.
Hospital stay days Coefficient 95% conf. interval p value
Sex -0.86 (-5.36, 3.63) 0.70
Age -0.24 (-0.45, -0.04) 0.02
Charlson Comorbidity Index Score 0.53 (-0.88, 1.96) 0.46
CRP (mg/dl) -0.01 (-0.04, 0.004) 0.11
NLI 0.13 (-0.19, 0.47) 0.40
RDW (%) -0.37 (-2.32, 1.56) 0.70
Ferritin (ng/ml) 0.001 (-0.001, 0.003) 0.34
Extraction day -0.41 (-1.78, 0.94) 0.55
IL-6 (pg/ml) 6.78 (9.60, 3.96) <0.001
LDH: lactate dehydrogenase; CRP: C-reactive Protein; NLI: Neutrophil/Lymphocyte index; RDW: Red Cell Distribution Width; IL-6: Interleukin 6. ∗LDH was
excluded because of collinearity.
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so-called cytokine storm leads to T cell dysfunction and
peripheral lymphopenia in most admitted patients and there-
fore evolving to severe forms of the disease [1]. In this con-
text, anticytokine treatment has been widely demonstrated
as useful in rheumatologic diseases (anakinra, tocilizumab,
or baricitinib, for example), being administrated to infected
patients all over the world with promising results [23] in an
attempt to attenuate the host immune response to SARS-
CoV-2 pathogen and associated inflammatory features. In
fact, these therapies as well as glucocorticoids were included
in our own centre protocol, with successful outcomes in
hospitalised cases [7].
The cytokine storm resulting from the release of inflam-
matory mediators induces endothelial activation, capillary
leak, circulatory collapse, clotting, and microvascular
obstruction [11]. In addition, SARS-COV-2 triggers complex
molecular events related to hyperinflammation with a puta-
tive role for IL-6, where several molecular axes associated to
ACE-2 are involved [9].
In addition, there are evidences of a relationship between
proinflammatory profiles and the personalised response to
SARS-CoV-2 infection, which is also found in this cohort.
Underlying diabetes (baseline hyperglycaemia) [24] and car-
diovascular diseases and risks (hypertension, dyslipidaemia,
smoking) worsen clinical outcomes to viral infections [25].
Indeed, serologic markers (IL-6 and CRP, for example) are
elevated in patients with these inflammatory-related comor-
bidities linked to an endothelial damage, which is possibly
due to potentiating “stormy” synergic influences. A meta-
analysis showed a higher probability of sickness, develop-
ment of severe symptoms, and fatal outcomes similar to
those described according to MERS (Middle East Respiratory
Syndrome) infection [26]. Furthermore, “inflammaging”
[27] and obesity [28] are other conditions related with
COVID-19 symptoms, prognosis, and adverse clinical
consequences.
According to our results, IL-6 and the assessed inflam-
matory biomarkers followed analogous patterns. Thus, fer-
ritin and the NLI showed statistically significant
associations with mortality rates. Moreover, ARDS related
to COVID-19 pneumonia generates a virally induced
immunosuppression similar to primary haemophagocytic
lymphohistocytosis [29]. This finding is a possible explana-
tion of the shared analytical features concerning the macro-
phage activation-like syndrome such as hyperferritinaemia,
abnormal hepatic profile, or coagulopathy. McGonagle
et al. [30] showed that the macrophagic activation syn-
drome in SARS-COV-2 infection is related to nonsurvival
in these subjects as well as IL-6 and IL-1 elevation. In addi-
tion, high viral load and continued exposure to the virus
could be an important factor for the severity of disease
[31]. Interestingly, the Charlson Comorbidity Index Score,
transaminases, and CRP values exhibited the expected
trends concerning inflammatory processes depending on
circulating IL-6 levels [32].
In this context, NLI revealed a parallel trend with IL-6
and hospitalisation stage, ICU admission, and mortality rate
in our series. NLI has emerged as an affordable inflammatory
clinical marker with a predicting role in cancer, infectious
diseases, cardiovascular complications, or autoimmune dis-
ease disorders [33, 34]. Necropsy data in SARS-COV-2-
infected patients is low, but impaired myelopoiesis and lym-
phohematopoietic system involvement was noted within a
hyperinflammation status, whose progression may have a
high discrimination level in severe cases affecting inflamma-
tion mediators [35].
Some limitations cannot be denied. A cohort of 165
cases may not be representative of the whole population,
which makes it convenient to validate these outcomes by
further investigations. In any case, the achieved results
are compatible with existing scientific evidences [36]. The
absence of statistical significance in some biomarkers
may be due to the relatively low number of subjects, but
Table 4: Odds ratio (OR) for UCI admission adjusted by age, sex,









Sex 1.55 (0.25, 9.71) 0.64
Age 0.93 (0.86, 1.00) 0.06
Charlson Comorbidity Index
Score
0.56 (0.26, 1.22) 0.14
LDH (U/l) 0.99 (0.98, 1.00) 0.06
CRP (mg/dl) 1.00 (0.99, 1.00) 0.64
NLI 1.08 (0.99, 1.17) 0.07
RDW (%) 1.07 (0.43, 2.63) 0.89
Ferritin (ng/ml) 1.00 (0.99, 1.00) 0.40
Extraction day 0.67 (0.40, 1.12) 0.12
IL-6 (pg/ml) 24.93 (2.49, 249.63) 0.006
LDH: lactate dehydrogenase; CRP: C-reactive Protein; NLI:
Neutrophil/Lymphocyte index; RDW: Red Cell Distribution Width; IL-6:
Interleukin 6.
Table 5: Odds ratio (OR) for in-hospital mortality adjusted by age,
sex, Charlson Comorbidity Index Score, and main analytical values








Sex 10.12 (1.09, 94.18) 0.04
Age 1.19 (1.05, 1.34) 0.007
Charlson Comorbidity Index
Score
1.30 (0.76, 2.22) 0.33
LDH (U/l) 0.99 (0.98, 1.00) 0.23
CRP (mg/dl) 1.00 (0.99, 1.01) 0.84
NLI 1.20 (1.02, 1.42) 0.03
RDW (%) 1.20 (0.66, 2.18) 0.55
Ferritin (ng/ml) 1.00 (1.002, 1.003) 0.02
Extraction day 0.74 (0.36, 1.52) 0.41
IL-6 (pg/ml) 9.81 (1.56, 61.69) 0.02
LDH: lactate dehydrogenase; CRP: C-reactive Protein; NLI:
Neutrophil/Lymphocyte index; RDW: Red Cell Distribution Width; IL-6:
Interleukin 6.
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despite type 1 and type 2 statistical errors cannot be dis-
carded, our results are clinically plausible. The extraction
day of the blood samples may also induce a bias in some
analyses, which was minimised with an adjusted multivar-
iate model. Despite ferritin data are statistically significant,
caution should be paid when interpreting such results
given the small size magnitude found in this cohort. As
for strengths, the homogeneity of the sample is a remark-
able point due that the same protocol was followed by all
clinicians in our hospital. In addition, the high sensitivity
and specificity of IL-6 as the main serologic biomarker is
another positive issue of the study. Indeed, the consider-
ation of lifestyle factors (smoking and alcoholic drinking),
body adiposity, and accompanying comorbidities in the
inflammatory analyses [37, 38] adds great value to the cur-
rent data since they were not usually screened in previous
COVID-19 publications.
As a corollary, this research reproduces not only the
validity of IL-6 as a prognostic COVID-19 factor but also
demonstrated relevant associations and interactions with
various inflammatory functions. These findings are in agree-
ment with the suspected underlying physiopathological
mechanisms induced by viral infections and providing addi-
tional information about other inflammatory contributors
such as NLI, ferritin, and RDW that explain the assessed
clinical outcomes and correlations with metabolically related
comorbidities. Indeed, IL-6 measurements evidenced a
worthy association with days of hospital stay days, ICU
admission, and mortality rates with affordable value for




BMI: Body Mass Index
CRP: C-reactive Protein
DBP: Diastolic Blood Pressure




RDW: Red Cell Distribution Width
SBP: Systolic Blood Pressure.
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